You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDextropropoxyphene
Accession NumberDB00647  (APRD00548)
TypeSmall Molecule
GroupsApproved, Illicit, Withdrawn
DescriptionDextropropoxyphene is an analgesic in the opioid category, patented (1955) and manufactured by Eli Lilly and Company. It is intended to treat mild pain and also has antitussive and local anaesthetic effects. The drug has been taken off the market in Europe and the US due to concerns of fatal overdoses and heart arrhythmias. An estimated 10 million patients have used these products. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.
Structure
Thumb
Synonyms
d-Propoxyphene
Destropropossifene
Dextropropoxifeno
Dextropropoxyphen
Dextropropoxyphène
Dextropropoxyphenum
External Identifiers
  • L 16298
  • SK 65
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
642 Tabtablet65 mgoralPendopharm Division Of De Pharmascience Inc1968-12-312010-11-25Canada
Darvon-Ncapsule100 mgoralPaladin Labs Inc1973-12-312010-12-23Canada
Novo-propoxyn Cap 65mgcapsule65 mgoralNovopharm Limited1970-12-312005-08-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Propoxyphenecapsule65 mg/1oralStat Rx USA2009-10-27Not applicableUs
Propoxyphene Hydrochloridecapsule65 mg/1oralHeritage Pharmaceuticals Inc2009-05-01Not applicableUs
Propoxyphene Hydrochloridecapsule65 mg/1oralbryant ranch prepack2009-12-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbalginDLF
DacotonStandard
DarvonEli Lilly
DeprancolParke Davis
DepronalPfizer
DoleneNot Available
DoloxeneAspen Pharmacare
Brand mixtures
NameLabellerIngredients
692 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
692 TabletLioh Inc.
Darvon N Compound Pulvule 405Eli Lilly Canada Inc
Novo-propoxyn Compound CapNovopharm Limited
Propoxyphene Hydrochloride and AcetaminophenMylan Pharmaceuticals Inc.
Salts
Name/CASStructureProperties
Dextropropoxyphene Hydrochloride
1639-60-7
Thumb
  • InChI Key: QMQBBUPJKANITL-MYXGOWFTSA-N
  • Monoisotopic Mass: 375.196506916
  • Average Mass: 375.932
DBSALT000500
Dextropropoxyphene Napsylate
ThumbNot applicableDBSALT001000
Categories
UNIIS2F83W92TK
CAS number469-62-5
WeightAverage: 339.4712
Monoisotopic: 339.219829177
Chemical FormulaC22H29NO2
InChI KeyInChIKey=XLMALTXPSGQGBX-PEODTPIXNA-N
InChI
InChI=1/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/s2
IUPAC Name
(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl propanoate
SMILES
CCC(=O)O[C@@](CC1=CC=CC=C1)([[email protected]](C)CN(C)C)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassStilbenes
Sub ClassNot Available
Direct ParentStilbenes
Alternative Parents
Substituents
  • Stilbene
  • Phenylbutylamine
  • Phenylpropylamine
  • Benzyloxycarbonyl
  • Phenylpropane
  • Aralkylamine
  • Benzenoid
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
  • 1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate (CHEBI:51173 )
Pharmacology
IndicationFor the relief of mild to moderate pain
PharmacodynamicsPropoxyphene, a synthetic opiate agonist, is structurally similar to methadone. Its general pharmacologic properties are those of the opiates as a group. The analgesic effect of propoxyphene is due to the d-isomer, dextropropoxyphene. It binds to the opiate receptors and leads to a decrease of the perception of pain stimuli. Propoxyphene possesses little to no antitussive activity and no antipyretic action.
Mechanism of actionPropoxyphene acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Propoxyphene primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as propoxyphene also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 16 L/kg
Protein bindingNot Available
Metabolism

Hepatic

Route of eliminationThe major route of metabolism is cytochrome CYP3A4 mediated N-demethylation to norpropoxyphene, which is excreted by the kidneys. In 48 hours, approximately 20% to 25% of the administered dose of propoxyphene is excreted via the urine, most of which is free or conjugated norpropoxyphene.
Half life6-12 hours
Clearance
  • 2.6 L/min
ToxicityComa, respiratory depression, circulatory collapse, and pulmonary edema. Seizures occur more frequently in patients with propoxyphene intoxication than in those with opiate intoxication. LD50=230mg/kg (orally in rat, Emerson)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Propoxyphene Action PathwayDrug actionSMP00672
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.997
Blood Brain Barrier+0.9503
Caco-2 permeable+0.7277
P-glycoprotein substrateSubstrate0.5798
P-glycoprotein inhibitor IInhibitor0.7851
P-glycoprotein inhibitor IINon-inhibitor0.6469
Renal organic cation transporterNon-inhibitor0.6086
CYP450 2C9 substrateNon-substrate0.833
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.6032
CYP450 1A2 substrateInhibitor0.6357
CYP450 2C9 inhibitorNon-inhibitor0.7637
CYP450 2D6 inhibitorInhibitor0.6887
CYP450 2C19 inhibitorNon-inhibitor0.7628
CYP450 3A4 inhibitorNon-inhibitor0.7992
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.646
Ames testNon AMES toxic0.8896
CarcinogenicityCarcinogens 0.7164
BiodegradationNot ready biodegradable0.9714
Rat acute toxicity2.9360 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9033
hERG inhibition (predictor II)Inhibitor0.6837
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Xanodyne pharmaceutics inc
  • Heritage pharmaceuticals inc
  • Mk laboratories inc
  • Halsey drug co inc
  • Alra laboratories inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nexgen pharma inc
  • Par pharmaceutical inc
  • Purepac pharmaceutical co
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Valeant pharmaceuticals international
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Warner chilcott div warner lambert co
  • Aaipharma llc
Packagers
Dosage forms
FormRouteStrength
Tabletoral65 mg
Tabletoral
Capsuleoral
Capsuleoral100 mg
Capsuleoral65 mg
Capsuleoral65 mg/1
Tablet, film coatedoral
Prices
Unit descriptionCostUnit
Propoxyphene napsylate powder5.33USD g
Darvon-n 100 mg tablet2.16USD tablet
Darvon 65 mg capsule1.71USD capsule
Propoxyphene N-APAP 100-500 mg tablet1.6USD tablet
Darvon 65 mg pulvule1.49USD each
Propoxyphene N-APAP 50-325 mg tablet1.32USD tablet
Propoxyphene-APAP 65-650 mg tablet0.57USD tablet
Propoxyphene N-APAP 100-650 mg tablet0.47USD tablet
Propoxyphene hcl 65 mg capsule0.43USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point75.5 °CPhysProp
water solubility3.32 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP4.18HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00419 mg/mLALOGPS
logP4.06ALOGPS
logP4.9ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)9.52ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity102.88 m3·mol-1ChemAxon
Polarizability38.86 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-0a4i-9200000000-39d80ee06dde3e5036f4View in MoNA
References
Synthesis Reference

Carl R. White, “Synthesis and purification of d-propoxyphene hydrochloride.” U.S. Patent US4661625, issued April, 1973.

US4661625
General References
  1. Coda BA, Rudy AC, Archer SM, Wermeling DP: Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg. 2003 Jul;97(1):117-23, table of contents. [PubMed:12818953 ]
External Links
ATC CodesN02AC54N02AC74N02AC04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (46.1 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dextropropoxyphene.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Dextropropoxyphene.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with 7-Nitroindazole.
AcepromazineAcepromazine may increase the hypotensive activities of Dextropropoxyphene.
AcepromazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dextropropoxyphene.
adipiplonThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alfentanil.
AlimemazineAlimemazine may increase the hypotensive activities of Dextropropoxyphene.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dextropropoxyphene.
AlvimopanThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amiloride.
AmiodaroneThe metabolism of Dextropropoxyphene can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Dextropropoxyphene which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amobarbital.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Dextropropoxyphene.
AmoxapineDextropropoxyphene may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dextropropoxyphene.
AmperozideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Dextropropoxyphene.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dextropropoxyphene.
AprepitantThe serum concentration of Dextropropoxyphene can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Asenapine.
AtazanavirThe metabolism of Dextropropoxyphene can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Dextropropoxyphene can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dextropropoxyphene.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dextropropoxyphene.
AzaperoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Azaperone.
AzelastineDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dextropropoxyphene.
AzosemideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dextropropoxyphene.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dextropropoxyphene.
BenzocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Dextropropoxyphene.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Bexarotene.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Dextropropoxyphene.
BoceprevirThe metabolism of Dextropropoxyphene can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Dextropropoxyphene can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.
BrimonidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dextropropoxyphene.
BuprenorphineBuprenorphine may decrease the analgesic activities of Dextropropoxyphene.
BuprenorphineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dextropropoxyphene.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dextropropoxyphene.
ButacaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Dextropropoxyphene.
ButorphanolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Butorphanol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dextropropoxyphene.
CarbinoxamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carisoprodol.
CeritinibThe serum concentration of Dextropropoxyphene can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dextropropoxyphene.
ChlormezanoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chloroprocaine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dextropropoxyphene.
ChlorphentermineChlorphentermine may increase the analgesic activities of Dextropropoxyphene.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Dextropropoxyphene.
ChlorpromazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dextropropoxyphene.
CitalopramDextropropoxyphene may increase the serotonergic activities of Citalopram.
ClarithromycinThe metabolism of Dextropropoxyphene can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Dextropropoxyphene can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with clomethiazole.
ClomipramineDextropropoxyphene may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dextropropoxyphene.
ClonazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dextropropoxyphene.
ClotrimazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dextropropoxyphene.
CobicistatThe metabolism of Dextropropoxyphene can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dextropropoxyphene.
ConivaptanThe serum concentration of Dextropropoxyphene can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Conivaptan.
CrizotinibThe metabolism of Dextropropoxyphene can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dextropropoxyphene.
CyclosporineThe metabolism of Dextropropoxyphene can be decreased when combined with Cyclosporine.
CyclothiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyproheptadine.
DabrafenibThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dextropropoxyphene.
DapoxetineDextropropoxyphene may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dextropropoxyphene.
DarunavirThe metabolism of Dextropropoxyphene can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Dextropropoxyphene can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Dextropropoxyphene can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dextropropoxyphene.
DesmopressinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Detomidine.
DexamethasoneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dextropropoxyphene.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dextropropoxyphene.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Dextropropoxyphene.
DextromoramideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dextromoramide.
DezocineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Diazepam.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextropropoxyphene.
DifenoxinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Dextropropoxyphene can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydromorphine.
DiltiazemThe metabolism of Dextropropoxyphene can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Doxepin.
DoxycyclineThe metabolism of Dextropropoxyphene can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.
DoxylamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.
DronedaroneThe metabolism of Dextropropoxyphene can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Dextropropoxyphene.
DrospirenoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dextropropoxyphene.
EcgonineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Efonidipine.
EluxadolineDextropropoxyphene may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dextropropoxyphene.
EntacaponeThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Entacapone.
EnzalutamideThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Eplerenone.
ErythromycinThe metabolism of Dextropropoxyphene can be decreased when combined with Erythromycin.
EscitalopramDextropropoxyphene may increase the serotonergic activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dextropropoxyphene.
Etacrynic acidThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etacrynic acid.
EthanolDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Dextropropoxyphene.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextropropoxyphene.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dextropropoxyphene.
EthosuximideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dextropropoxyphene.
EtoperidoneDextropropoxyphene may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etorphine.
EtravirineThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fencamfamine.
FenfluramineDextropropoxyphene may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextropropoxyphene.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dextropropoxyphene.
FexofenadineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flibanserin.
FluconazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flunitrazepam.
FluoxetineDextropropoxyphene may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Dextropropoxyphene.
FluphenazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fluticasone Propionate.
FluvoxamineDextropropoxyphene may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Dextropropoxyphene can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Dextropropoxyphene can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Dextropropoxyphene can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Furosemide.
Fusidic AcidThe serum concentration of Dextropropoxyphene can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dextropropoxyphene.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Dextropropoxyphene.
GuanfacineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dextropropoxyphene.
HalothaneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dextropropoxyphene.
HexobarbitalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dextropropoxyphene.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hydrocodone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextropropoxyphene.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Dextropropoxyphene.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.
HydroxyzineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dextropropoxyphene.
IdelalisibThe serum concentration of Dextropropoxyphene can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Iloperidone.
ImatinibThe metabolism of Dextropropoxyphene can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Imipramine.
IndalpineDextropropoxyphene may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Indapamide.
IndinavirThe metabolism of Dextropropoxyphene can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dextropropoxyphene.
IsavuconazoniumThe metabolism of Dextropropoxyphene can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Isoflurane.
IsosorbideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Isosorbide.
IsradipineThe metabolism of Dextropropoxyphene can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Dextropropoxyphene can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketobemidone.
KetoconazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levomethadyl Acetate.
LevomilnacipranDextropropoxyphene may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dextropropoxyphene.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Dextropropoxyphene.
LithiumThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lofentanil.
LopinavirThe metabolism of Dextropropoxyphene can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dextropropoxyphene.
LovastatinThe metabolism of Dextropropoxyphene can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dextropropoxyphene.
Lu AA21004Dextropropoxyphene may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Dextropropoxyphene.
LuliconazoleThe serum concentration of Dextropropoxyphene can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dextropropoxyphene.
MeclizineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Dextropropoxyphene.
MepivacaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dextropropoxyphene.
MersalylThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Dextropropoxyphene.
MesoridazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dextropropoxyphene.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Dextropropoxyphene.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dextropropoxyphene.
MethapyrileneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dextropropoxyphene.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Dextropropoxyphene.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Dextropropoxyphene.
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Dextropropoxyphene.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methylphenobarbital.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Dextropropoxyphene.
MetolazoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dextropropoxyphene.
MetyrosineDextropropoxyphene may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Midazolam.
MifepristoneThe metabolism of Dextropropoxyphene can be decreased when combined with Mifepristone.
MilnacipranDextropropoxyphene may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.
MirtazapineDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dextropropoxyphene.
MitotaneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Dextropropoxyphene.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dextropropoxyphene.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Dextropropoxyphene.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.
NabiloneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nabilone.
NafcillinThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Dextropropoxyphene.
NalbuphineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nalbuphine.
NaloxegolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Naloxegol.
NaltrexoneThe therapeutic efficacy of Dextropropoxyphene can be decreased when used in combination with Naltrexone.
NefazodoneThe metabolism of Dextropropoxyphene can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Dextropropoxyphene can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Dextropropoxyphene can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Dextropropoxyphene can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Dextropropoxyphene can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Dextropropoxyphene.
NitrazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Dextropropoxyphene.
OlanzapineDextropropoxyphene may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dextropropoxyphene.
OlaparibThe metabolism of Dextropropoxyphene can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Opium.
OrphenadrineDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dextropropoxyphene.
OsanetantThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Osanetant.
OsimertinibThe serum concentration of Dextropropoxyphene can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxybuprocaine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dextropropoxyphene.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dextropropoxyphene.
OxymorphoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dextropropoxyphene.
PalbociclibThe serum concentration of Dextropropoxyphene can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dextropropoxyphene.
ParaldehydeDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Dextropropoxyphene.
ParoxetineDextropropoxyphene may increase the serotonergic activities of Paroxetine.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextropropoxyphene.
PentazocinePentazocine may decrease the analgesic activities of Dextropropoxyphene.
PentazocineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dextropropoxyphene.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dextropropoxyphene.
PerampanelThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Dextropropoxyphene.
PerphenazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dextropropoxyphene.
PhenobarbitalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Dextropropoxyphene.
PhenytoinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dextropropoxyphene.
PipotiazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dextropropoxyphene.
PiretanideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pomalidomide.
PosaconazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Potassium Citrate.
PramipexoleDextropropoxyphene may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dextropropoxyphene.
PrilocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Procaine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Dextropropoxyphene.
ProchlorperazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dextropropoxyphene.
PromazinePromazine may increase the hypotensive activities of Dextropropoxyphene.
PromazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Dextropropoxyphene.
PromethazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dextropropoxyphene.
ProparacaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dextropropoxyphene.
RamelteonThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ramelteon.
RamosetronDextropropoxyphene may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Dextropropoxyphene can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dextropropoxyphene.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dextropropoxyphene.
RifabutinThe metabolism of Dextropropoxyphene can be increased when combined with Rifabutin.
RifampicinThe metabolism of Dextropropoxyphene can be increased when combined with Rifampicin.
RifapentineThe metabolism of Dextropropoxyphene can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Risperidone.
RitonavirThe metabolism of Dextropropoxyphene can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Romifidine.
RopiniroleDextropropoxyphene may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dextropropoxyphene.
RotigotineDextropropoxyphene may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dextropropoxyphene.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Dextropropoxyphene can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dextropropoxyphene.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dextropropoxyphene.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dextropropoxyphene.
SertindoleThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sertindole.
SertralineDextropropoxyphene may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sevoflurane.
SildenafilThe metabolism of Dextropropoxyphene can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Dextropropoxyphene can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dextropropoxyphene.
SpironolactoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Spironolactone.
St. John's WortThe serum concentration of Dextropropoxyphene can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Dextropropoxyphene.
SufentanilThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sufentanil.
SulfisoxazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dextropropoxyphene.
SuvorexantThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tasimelteon.
TelaprevirThe metabolism of Dextropropoxyphene can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Dextropropoxyphene can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dextropropoxyphene.
TetrabenazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tetrodotoxin.
ThalidomideDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dextropropoxyphene.
TheobromineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Dextropropoxyphene.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dextropropoxyphene.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Dextropropoxyphene.
ThioridazineThioridazine may increase the hypotensive activities of Dextropropoxyphene.
ThiothixeneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tiagabine.
TiclopidineThe metabolism of Dextropropoxyphene can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Dextropropoxyphene.
TizanidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tizanidine.
TocilizumabThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dextropropoxyphene.
TolvaptanThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dextropropoxyphene.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tranylcypromine.
TrazodoneDextropropoxyphene may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dextropropoxyphene.
TriamtereneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Dextropropoxyphene.
TrifluoperazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Dextropropoxyphene.
TriflupromazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dextropropoxyphene.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dextropropoxyphene.
TrimipramineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dextropropoxyphene.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dextropropoxyphene.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dextropropoxyphene.
UlaritideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Dextropropoxyphene.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dextropropoxyphene.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dextropropoxyphene.
VenlafaxineThe metabolism of Dextropropoxyphene can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Dextropropoxyphene can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Vigabatrin.
VilazodoneDextropropoxyphene may increase the serotonergic activities of Vilazodone.
VoriconazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Voriconazole.
VortioxetineDextropropoxyphene may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Dextropropoxyphene.
XylazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ziconotide.
ZimelidineDextropropoxyphene may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe metabolism of Dextropropoxyphene can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dextropropoxyphene.
ZonisamideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Ulens C, Daenens P, Tytgat J: Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res. 1999 Dec;44(3):568-78. [PubMed:10690289 ]
  3. Tyers MB: A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol. 1980 Jul;69(3):503-12. [PubMed:6249436 ]
  4. Picker MJ: Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists. J Pharmacol Exp Ther. 1997 Dec;283(3):1009-17. [PubMed:9399970 ]
  5. Codd EE, Shank RP, Schupsky JJ, Raffa RB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995 Sep;274(3):1263-70. [PubMed:7562497 ]
  6. Bannwarth B, Richez C: The dextropropoxyphene controversy. Joint Bone Spine. 2009 Oct;76(5):449-51. doi: 10.1016/j.jbspin.2009.04.004. Epub 2009 Jul 14. [PubMed:19604717 ]
  7. Walker EA, Tiano MJ, Benyas SI, Dykstra LA, Picker MJ: Naltrexone and beta-funaltrexamine antagonism of the antinociceptive and response rate-decreasing effects of morphine, dezocine, and d-propoxyphene. Psychopharmacology (Berl). 1999 May;144(1):45-53. [PubMed:10379623 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Neil A: Affinities of some common opioid analgesics towards four binding sites in mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1984 Nov;328(1):24-9. [PubMed:6151117 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Neil A: Affinities of some common opioid analgesics towards four binding sites in mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1984 Nov;328(1):24-9. [PubMed:6151117 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23